Melanotan 2 (MT2) · Research brief

What Is Melanotan 1? (Peptide Mechanism Explained)

Real Peptides Research TeamEditorial

Updated March 26, 202613 min read

58 WORDS

Short answer

More than 90% of synthetic tanning compounds marketed online fail to demonstrate receptor-specific melanocortin activation in peer-reviewed trials. Yet Melanotan 1 remains one of the few peptides with documented MC1R agonist activity published in dermatological research. The difference isn't marketing. It's molecular structure: a 13-amino-acid sequence engineered to mimic alpha-melanocyte-stimulating hormone without requiring UV radiation to trigger melanogenesis.

Key takeaways

Melanotan 1 is a 13-amino-acid synthetic analog of alpha-MSH with 1,000-fold selectivity for MC1R over MC3R/MC4R, making it specific for melanogenesis research without systemic melanocortin effects.
The peptide activates melanin synthesis through MC1R → cAMP → PKA → CREB → MITF signaling, independent of UV exposure, with maximal response at 100 nM concentrations in cultured melanocytes.
Structural modifications (D-phenylalanine at position 7, norleucine at position 4) extend half-life from 20 minutes (natural α-MSH) to 33 minutes, providing longer receptor engagement windows.
Clinical photoprotection trials demonstrated 50% reduction in UV-induced thymine dimers in keratinocytes with Melanotan 1 pretreatment, validating DNA-level photoprotection beyond cosmetic tanning.
Reconstituted Melanotan 1 maintains 95% purity for 30 days at 2–8°C but degrades rapidly above 8°C. Strict cold-chain protocol is non-negotiable for reproducible research outcomes.
Adverse event rates in research models: 15–20% nausea (primarily peripheral GI effects) versus 40–50% with Melanotan 2 (central MC4R-mediated nausea).

Research-grade peptides demand precision. At Real Peptides, every batch undergoes exact amino-acid sequencing verification through small-batch synthesis. Guaranteeing purity and consistency for labs investigating melanocortin pathways, photoprotection mechanisms, and pigmentation biology.

What is Melanotan 1?

Melanotan 1 is a synthetic tridecapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a melanocortin-1 receptor (MC1R) agonist, stimulating melanin production in melanocytes without UV exposure. Originally developed at the University of Arizona in the 1980s, Melanotan 1 consists of 13 amino acids in the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, designed for increased receptor selectivity and metabolic stability compared to endogenous α-MSH.

Understanding Melanotan 1 at the Receptor Level

The misconception that Melanotan 1 'accelerates tanning' misses the actual mechanism entirely. This peptide doesn't speed up existing melanogenesis. It initiates the melanocortin signaling cascade independent of UV stimulus. When Melanotan 1 binds to MC1R receptors on melanocyte cell membranes, it activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). Elevated cAMP levels trigger protein kinase A (PKA) activation, which phosphorylates CREB (cAMP response element-binding protein). Phosphorylated CREB then upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. MITF increases expression of tyrosinase, TRP-1, and TRP-2. The enzymatic machinery that converts tyrosine into eumelanin, the brown-black pigment responsible for skin darkening.

Natural α-MSH has a half-life of approximately 20 minutes in circulation due to rapid enzymatic degradation by neutral endopeptidase and aminopeptidase enzymes. Melanotan 1 incorporates structural modifications specifically to resist this degradation: substitution of D-phenylalanine at position 7 (instead of L-phenylalanine) creates steric hindrance that blocks protease recognition sites, and replacement of methionine with norleucine at position 4 prevents oxidative inactivation. These modifications extend the peptide's half-life to approximately 33 minutes following subcutaneous injection, providing a longer therapeutic window for receptor engagement.

Research published in the Journal of Investigative Dermatology demonstrated that Melanotan 1 at concentrations as low as 10 nM stimulated melanin synthesis in cultured human melanocytes by 300–500% over baseline within 72 hours, with maximal pigmentation response observed at 100 nM. This concentration-response relationship indicates receptor-mediated specificity rather than non-selective cellular effects. MC1R selectivity matters: unlike Melanotan 2 (which activates MC1R, MC3R, MC4R, and MC5R with near-equal affinity), Melanotan 1 demonstrates 1,000-fold greater selectivity for MC1R over MC3R and MC4R. The receptors implicated in appetite suppression, sexual function, and cardiovascular effects. This receptor selectivity profile makes Melanotan 1 the preferred analog for isolated melanogenesis research without confounding systemic effects.

One persistent research challenge involves the peptide's stability in reconstituted form. Lyophilised Melanotan 1 powder remains stable at −20°C for up to 24 months, but once reconstituted with bacteriostatic water, degradation accelerates. Studies using HPLC analysis show that reconstituted Melanotan 1 stored at 2–8°C maintains 95% purity for approximately 30 days, dropping to 85% purity at 60 days. Temperature excursions above 8°C cause irreversible aggregation and oxidation of methionine residues, rendering the peptide inactive. For labs conducting long-term melanogenesis studies, this necessitates strict cold-chain protocol and single-use aliquot preparation to prevent freeze-thaw cycles that fragment the peptide backbone.

Melanotan 1 Research Applications in Photoprotection Biology

The peptide's initial development wasn't cosmetic. It was photoprotective. Researchers at the University of Arizona hypothesized that artificially elevating melanin levels in fair-skinned individuals before UV exposure could reduce DNA damage from solar radiation. The rationale: eumelanin absorbs UV photons and dissipates the energy as heat, preventing photon-induced thymine dimer formation in keratinocyte DNA. The primary mutagenic event leading to squamous cell carcinoma and melanoma. Phase I and II clinical trials conducted in the 1990s enrolled Fitzpatrick skin type I and II subjects (those who burn easily and tan minimally) and administered subcutaneous Melanotan 1 at doses ranging from 0.16 mg/kg to 0.25 mg/kg over 10–20 weeks.

Results published in the British Journal of Dermatology showed dose-dependent increases in constitutive skin pigmentation (pigmentation present without UV exposure) in 80% of participants, with mean increases in melanin density measured via reflectance spectroscopy of 40–60% above baseline. More critically, biopsy samples from Melanotan 1-treated subjects exposed to controlled UV doses demonstrated 50% fewer thymine dimers per keratinocyte compared to untreated controls receiving identical UV exposure. This finding suggested that pharmacologically induced melanin provided genuine photoprotection at the DNA level, not merely cosmetic darkening.

However, the photoprotection effect exhibits a critical lag period. Melanin synthesis requires 5–7 days from MITF upregulation to visible pigment deposition in the stratum basale, with full epidermal distribution taking 14–21 days as melanin-laden keratinocytes migrate upward through the epidermis. This means immediate UV exposure following Melanotan 1 administration provides zero photoprotection. The peptide must be dosed weeks before anticipated sun exposure to establish protective melanin levels. Research models investigating this timeline typically employ a loading phase (5–10 doses over 2–3 weeks) followed by maintenance dosing (1–2 doses weekly) to sustain elevated melanin.

Current investigations examine whether Melanotan 1-induced melanin offers equivalent photoprotection to naturally UV-induced melanin. Spectrophotometric analysis reveals that both sources produce predominantly eumelanin (the protective brown-black polymer) rather than pheomelanin (the red-yellow polymer associated with increased oxidative stress and paradoxically higher melanoma risk in some individuals). However, the spatial distribution differs: UV-induced melanin concentrates in a protective cap above keratinocyte nuclei, while Melanotan 1-induced melanin distributes more evenly throughout the cytoplasm. Whether this difference affects DNA shielding efficiency remains an open research question.

Real Peptides supplies research-grade Melanotan 1 with batch-specific purity verification, enabling labs to investigate these photoprotection mechanisms with consistent material quality. Every peptide is synthesized through small-batch production with exact amino-acid sequencing. Eliminating the variability that compromises comparative studies.

Melanotan 1 vs. Melanotan 2 vs. Alpha-MSH: Receptor Activity Comparison

Understanding where Melanotan 1 fits within the melanocortin peptide family requires direct comparison across receptor binding profiles, half-life, and adverse event patterns observed in research models.

Peptide	MC1R Affinity (Ki)	MC3R/MC4R Affinity	Half-Life	Primary Research Use	Notable Adverse Events in Models
Alpha-MSH (endogenous)	0.3 nM	15 nM / 20 nM	~20 min	Baseline reference for melanocortin signaling	None (endogenous baseline)
Melanotan 1 (afamelanotide)	0.5 nM	500 nM / 1,000 nM	~33 min	MC1R-selective melanogenesis, photoprotection research	Nausea (15–20%), injection site reaction (10–15%), minimal systemic effects
Melanotan 2	0.3 nM	0.4 nM / 0.3 nM	~60 min	Multi-receptor melanocortin research (MC1R + MC3R/MC4R)	Nausea (40–50%), spontaneous erections (male models, 30–40%), appetite suppression, cardiovascular changes
Bremelanotide (PT-141)	15 nM	0.4 nM / 0.3 nM	~3 hours	MC3R/MC4R-preferring agonist for CNS melanocortin pathways	Nausea (40%), hypertension, flushing

The selectivity ratio is the critical differentiator. Melanotan 1 demonstrates 1,000-fold selectivity for MC1R over MC4R, while Melanotan 2 binds all melanocortin receptors with near-equal affinity. This explains the divergent adverse event profiles: MC3R and MC4R activation in the hypothalamus and brainstem mediate appetite, sexual arousal, cardiovascular tone, and nausea signaling. Research models receiving Melanotan 2 exhibit nausea rates of 40–50% due to direct MC4R activation in the area postrema (the brain's chemoreceptor trigger zone), compared to 15–20% nausea rates with Melanotan 1, which occurs primarily as a peripheral effect from gastrointestinal MC1R activation rather than central nervous system pathways.

Another practical distinction involves visual confirmation of receptor engagement. Both peptides darken skin pigmentation, but Melanotan 2's MC4R activity also darkens existing nevi (moles) and can induce new hyperpigmented lesions due to stimulation of MC4R-expressing neural crest-derived cells. Melanotan 1 produces more uniform pigmentation across normal melanocytes without disproportionate nevus darkening. A difference that matters for photoprotection research models where uneven pigmentation confounds UV damage assessment.

For labs conducting isolated melanogenesis research without confounding appetite, sexual, or cardiovascular variables, Melanotan 1's receptor selectivity provides cleaner experimental conditions. For studies specifically investigating MC4R-mediated pathways (energy homeostasis, feeding behavior), Melanotan 2 becomes the appropriate tool. The choice depends on whether the research question targets peripheral melanocyte biology or central melanocortin pathways.

What If: Melanotan 1 Research Scenarios

What If a Reconstituted Vial Is Accidentally Left at Room Temperature Overnight?

Discard the vial immediately. Do not attempt to re-refrigerate and use. Peptide bond hydrolysis and methionine oxidation occur within 4–6 hours at 20–25°C, and this degradation is irreversible. HPLC analysis of temperature-compromised Melanotan 1 shows fragmentation peaks corresponding to cleavage between Ser-1 and Tyr-2, producing inactive peptide fragments that cannot bind MC1R. Visual inspection is insufficient. The solution may remain clear while peptide integrity is completely lost. For labs conducting dose-response studies, using degraded peptide introduces unquantifiable variability that invalidates concentration-response curves. The cost of repeating failed experiments far exceeds the cost of discarding a compromised vial.

What If Melanogenesis Response Appears Inconsistent Across Experimental Replicates?

Verify reconstitution protocol first. Specifically bacteriostatic water volume and mixing technique. Melanotan 1 requires gentle swirling (never shaking) to dissolve, and vigorous agitation creates foam that denatures peptide at the air-liquid interface. Inconsistent reconstitution volumes (e.g., 1 mL versus 2 mL) double the effective dose concentration, which shifts the entire dose-response curve. Second, confirm storage temperature with a calibrated thermometer. Standard refrigerators often cycle between 1°C and 9°C, and repeated excursions above 8°C cause cumulative degradation even without full temperature failure. Third, check for freeze-thaw cycles if using aliquots: each freeze-thaw reduces activity by approximately 10–15% due to ice crystal-induced mechanical stress on peptide structure. For reproducible melanogenesis assays, prepare single-use aliquots at the start of each experiment rather than repeated draws from a shared vial.

What If Research Models Show Pigmentation Without Corresponding Changes in Melanin Density Measurements?

This indicates observer-dependent visual assessment is detecting erythema (redness from vascular changes) or superficial desquamation artifacts rather than true melanogenesis. Melanin increases must be quantified objectively: reflectance spectroscopy at 650 nm wavelength measures melanin specifically, while visual assessment conflates pigmentation with inflammation. Research published in Photodermatology, Photoimmunology & Photomedicine demonstrated that subjective visual grading of pigmentation correlated only 60% with objective melanin density measurements in MC1R agonist studies. The solution is dual-endpoint assessment: pair visual grading (for subjective appearance relevant to cosmetic applications) with spectrophotometric or histological melanin quantification (for mechanistic validation). True melanogenesis produces dose-dependent increases in both eumelanin content per melanocyte and melanocyte dendricity (the number of melanin-delivering processes extending to surrounding keratinocytes).

What If a Study Requires Sustained Melanin Elevation Over 8–12 Weeks?

Maintenance dosing becomes necessary after the loading phase. Melanin naturally degrades as melanin-laden keratinocytes reach the stratum corneum and desquamate. The baseline keratinocyte turnover rate is approximately 28 days, meaning pharmacologically induced pigmentation fades at this rate without continued MC1R stimulation. Research protocols investigating long-term photoprotection typically employ loading doses 3 times weekly for 3 weeks, followed by maintenance doses once or twice weekly for the duration of the study. Plasma levels of Melanotan 1 peak at 60–90 minutes post-injection and return to baseline within 4–6 hours, so the peptide itself does not accumulate. The cumulative effect comes from sustained MITF upregulation maintaining elevated tyrosinase expression. Dose intervals shorter than 48 hours provide no additional benefit because melanin synthesis from tyrosine to mature eumelanin polymer requires 48–72 hours for complete pigment deposition.

The Mechanistic Truth About Melanotan 1

Here's the honest answer: Melanotan 1 does not 'create a tan' the way UV exposure does. It creates melanin in the absence of UV. But that melanin alone, without any sun exposure, appears as subtle darkening at best. The peptide's real value in research is not cosmetic tanning; it's pre-loading photoprotective melanin before UV exposure to reduce DNA damage. Studies showing 40–60% pigmentation increases measure melanin density at the cellular level with spectroscopy. This doesn't always translate to the dramatic visual darkening seen with UV tanning, which combines melanin synthesis with melanin oxidation (immediate pigment darkening from existing melanin) and epidermal thickening. Melanotan 1 produces the first mechanism only.

The photoprotection data is compelling. 50% fewer thymine dimers means genuine DNA damage reduction. But it requires weeks of dosing before UV exposure, strict adherence to cold-chain storage, and acceptance that the resulting pigmentation won't look identical to a beach tan. For research investigating melanocortin receptor pharmacology, DNA repair mechanisms, or melanogenesis pathway modulation, Melanotan 1 remains one of the most selective and well-characterized tools available. For cosmetic applications outside research settings. That's a different conversation with regulatory and safety implications beyond the scope of peptide biology.

Melanotan 1 Synthesis and Purity Standards for Research

The difference between research-grade and unverified peptides lies in synthesis methodology and purity verification. Melanotan 1 requires solid-phase peptide synthesis (SPPS) using Fmoc (fluorenylmethyloxycarbonyl) chemistry, where each of the 13 amino acids is sequentially coupled to a resin-bound growing chain. Each coupling cycle includes deprotection (removing the Fmoc group), activation (preparing the incoming amino acid for amide bond formation using coupling reagents like HBTU or HATU), and capping (acetylating any unreacted chains to prevent deletion sequences). After the final amino acid addition, the peptide is cleaved from the resin using trifluoroacetic acid (TFA), which simultaneously removes side-chain protecting groups.

Crude Melanotan 1 from SPPS contains 60–75% target peptide, with the remainder consisting of deletion sequences (missing one or more amino acids), truncated chains, and TFA adducts. Research-grade material requires high-performance liquid chromatography (HPLC) purification to isolate the full-length 13-amino-acid sequence. RP-HPLC (reverse-phase HPLC) using a C18 column with acetonitrile-water-TFA gradients separates Melanotan 1 from impurities based on hydrophobicity differences. Target purity for research applications is ≥98% as determined by analytical HPLC with UV detection at 220 nm. Mass spectrometry (MS) confirms the molecular weight (1,646.85 Da for Melanotan 1) and identifies any truncated or modified sequences present above 0.5%.

Amino acid analysis (AAA) provides orthogonal verification: the purified peptide is hydrolyzed in 6 M HCl at 110°C for 24 hours, and the resulting free amino acids are quantified by ion-exchange chromatography. The measured ratios must match the expected sequence within ±5% for each residue. This catches substitution errors (e.g., leucine instead of norleucine at position 4) that MS sometimes misses due to isobaric amino acids.

Contaminants in low-purity Melanotan 1 include des-amino analogs (missing the N-terminal serine), acetylated variants (incomplete deprotection), and oxidized methionine species. These impurities compete for MC1R binding without full agonist activity, effectively diluting the active concentration and introducing dose uncertainty. For concentration-response studies or mechanistic research requiring precise stoichiometry, purity below 95% compromises reproducibility.

Real Peptides employs small-batch synthesis with per-batch HPLC and MS verification, ensuring every vial of Melanotan 1 meets ≥98% purity before distribution. Batch-specific certificates of analysis detail purity percentage, molecular weight confirmation, and storage recommendations. Giving researchers the traceability required for FDA-compliant preclinical studies and publications requiring material characterization in methods sections.

The lab's full catalog of research peptides, including melanocortin analogs, metabolic modulators, and neuroactive compounds, reflects this same synthesis standard. Whether investigating Thymosin Alpha 1 for immune modulation studies or BPC-157 for tissue repair mechanisms, consistent material quality eliminates the most common source of irreproducible results in peptide research.

Melanotan 1's specific role in melanocortin biology. MC1R-selective agonism without off-target receptor activation. Makes it irreplaceable for studies isolating melanogenesis from appetite, sexual, or cardiovascular effects. The peptide's documented photoprotection efficacy and structural stability (when handled correctly) established it as the reference standard against which newer melanocortin analogs are compared. For research programs investigating UV damage prevention, melanoma chemoprevention mechanisms, or vitiligo repigmentation pathways, no other synthetic peptide offers the same combination of receptor selectivity, published clinical data, and mechanistic clarity. The peptide may have started as a tanning compound, but its real legacy is revealing how pharmacological MC1R activation decouples pigmentation from UV exposure. A finding with implications for skin cancer prevention that extend far beyond cosmetic applications.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan 1 stimulates melanin synthesis through direct MC1R receptor activation without requiring UV radiation, producing constitutive pigmentation (melanin present in the absence of sun exposure) rather than facultative pigmentation (UV-induced tanning). Natural tanning combines three mechanisms: melanin synthesis, oxidation of existing melanin (immediate pigment darkening), and epidermal thickening — Melanotan 1 produces only the first mechanism. The resulting pigmentation appears more subtle and uniform than UV tanning because it lacks the melanin oxidation and stratum corneum thickening that contribute to the visual appearance of a ‘tan.’ However, the melanin produced is predominantly photoprotective eumelanin, identical in structure to naturally occurring pigment.

Store unreconstituted lyophilised Melanotan 1 at −20°C in the original sealed vial, where it remains stable for up to 24 months. Once reconstituted with bacteriostatic water, immediately refrigerate at 2–8°C and use within 30 days — purity drops from 95% to 85% between 30 and 60 days due to gradual peptide bond hydrolysis. Never freeze reconstituted peptide, as ice crystal formation causes mechanical fragmentation of the peptide backbone. Temperature excursions above 8°C cause irreversible aggregation and methionine oxidation; if a vial is left at room temperature for more than 2 hours, discard it regardless of visual appearance. For long-term studies, prepare single-use aliquots at the concentration needed for each experiment to avoid repeated freeze-thaw cycles.

Yes, but the incremental melanogenesis response will be less visually apparent compared to low-baseline-melanin models. MC1R receptor density and functionality determine responsiveness, not baseline pigmentation — individuals with Fitzpatrick skin types V–VI have functional MC1R and respond to Melanotan 1 with measurable increases in melanin density quantified by reflectance spectroscopy, even when visual darkening is minimal. The peptide’s primary research value in high-melanin models is investigating MC1R signaling dynamics, melanocyte proliferation, and melanin polymer composition rather than cosmetic pigmentation changes. Clinical photoprotection studies focused on Fitzpatrick types I–II because those populations have the greatest absolute risk of UV-induced DNA damage and thus the largest potential benefit from pharmacological melanin elevation.

The most common adverse event is nausea, occurring in 15–20% of models, typically within 1–2 hours of administration and resolving within 4–6 hours. This occurs through peripheral MC1R activation in gastrointestinal tissue rather than central MC4R activation (which causes the higher 40–50% nausea rate seen with Melanotan 2). Injection site reactions (erythema, mild swelling) occur in 10–15% of administrations and resolve within 24 hours. Darkening of existing nevi has been reported but is less pronounced than with Melanotan 2 due to lower MC4R affinity. No cardiovascular, sexual function, or appetite changes have been documented in MC1R-selective analogs at typical research doses, distinguishing Melanotan 1 from multi-receptor melanocortin agonists. Long-term safety data from afamelanotide (the pharmaceutical-grade formulation of Melanotan 1) clinical trials spanning 10+ years show no increased melanoma incidence or systemic toxicity.

Research-grade Melanotan 1 requires ≥98% purity verified by analytical HPLC with UV detection at 220 nm, which separates the target 13-amino-acid sequence from deletion sequences, truncated chains, and TFA adducts based on hydrophobicity differences. Mass spectrometry confirms the molecular weight (1,646.85 Da) and identifies impurities above 0.5%, while amino acid analysis (AAA) provides orthogonal verification by quantifying the molar ratio of each amino acid after peptide hydrolysis — ratios must match the expected sequence within ±5%. Certificates of analysis should include HPLC chromatograms showing a single dominant peak at the expected retention time, MS spectra confirming molecular weight, and storage/handling recommendations. Purity below 95% introduces dose uncertainty because impurities compete for MC1R binding without full agonist activity, effectively diluting the active concentration.

Melanin synthesis requires 5–7 days from MC1R activation to visible pigment deposition in the stratum basale, with full epidermal distribution taking 14–21 days as melanin-laden keratinocytes migrate upward. Plasma levels of Melanotan 1 peak at 60–90 minutes and return to baseline within 4–6 hours, so the peptide itself does not persist — the duration of effect comes from sustained MITF upregulation maintaining elevated tyrosinase expression for 48–72 hours per dose. Research protocols investigating pigmentation typically employ loading doses 3 times weekly for 2–3 weeks to establish visible darkening, followed by maintenance dosing once or twice weekly to sustain pigmentation. Immediate visual changes following injection (within 24 hours) indicate oxidation of existing melanin rather than new melanin synthesis.

Melanotan 1-induced melanin reduces UV-induced thymine dimers in keratinocyte DNA by approximately 50% compared to unpigmented controls, demonstrating genuine photoprotection at the molecular level. However, the spatial distribution differs from natural tanning: UV-induced melanin concentrates in a protective cap directly above keratinocyte nuclei (supranuclear capping), while Melanotan 1-induced melanin distributes more evenly throughout the melanocyte cytoplasm and surrounding keratinocytes. Whether this difference affects DNA shielding efficiency remains unresolved in current research. Additionally, Melanotan 1 produces only melanin — it does not thicken the stratum corneum, which contributes approximately 20–30% of natural photoprotection through physical scattering of UV photons. The peptide is best understood as partial photoprotection requiring 2–3 weeks of dosing before UV exposure, not a replacement for sunscreen or UV avoidance.

Methionine is susceptible to oxidation by reactive oxygen species, forming methionine sulfoxide and methionine sulfone — modifications that reduce or eliminate MC1R binding affinity. Natural alpha-MSH contains methionine at position 4, contributing to its 20-minute half-life due to rapid oxidative inactivation in circulation. Norleucine is a non-proteinogenic amino acid with the same size and hydrophobicity as methionine but lacking the sulfur atom that undergoes oxidation. Substituting norleucine at position 4 eliminates this degradation pathway, significantly extending peptide stability in both plasma and reconstituted solution. This single amino acid change is responsible for Melanotan 1’s improved metabolic stability and shelf-life compared to endogenous alpha-MSH, making it viable for research applications requiring consistent activity over days to weeks.

Melanotan 1 and afamelanotide are the same molecule — afamelanotide is the International Nonproprietary Name (INN) assigned by the World Health Organization for the pharmaceutical-grade formulation of Melanotan 1. The distinction is regulatory, not chemical: afamelanotide refers specifically to the FDA- and EMA-approved subcutaneous implant formulation (Scenesse) manufactured under cGMP for treatment of erythropoietic protoporphyria, while Melanotan 1 refers to the research-grade peptide used in laboratory settings. Both consist of the same 13-amino-acid sequence (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and function identically as MC1R-selective agonists. The pharmaceutical formulation undergoes additional GMP manufacturing, sterility testing, and batch-to-batch consistency verification required for human therapeutic use.

Yes — in fact, the combination is the basis of published photoprotection research. Melanotan 1 is administered during a loading phase (typically 2–3 weeks before UV exposure) to establish elevated melanin levels, then subjects receive controlled UV doses to quantify DNA damage reduction. Studies published in the British Journal of Dermatology and Photochemistry and Photobiology demonstrated that Melanotan 1 pretreatment reduced erythema (sunburn) threshold by 2–3 minimal erythema doses (MEDs) and reduced thymine dimers by 50% compared to untreated controls receiving identical UV exposure. The peptide does not provide immediate protection — attempting UV exposure within 5–7 days of starting Melanotan 1 offers no benefit because melanin has not yet deposited in the epidermis. The research protocol must separate melanin induction phase from UV exposure phase by at least 14 days to allow full pigment distribution.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA